NovoCure (NVCR) Stock Price Target 2026

The average analyst price target for NovoCure is $26.86, 114.4% above the current price. Of 6 analysts, 4 rate it Buy and 2 Hold. Targets range from $15 to $52. The latest change came on Oct 30, 2026, when Wells Fargo lowered its price target on NovoCure from $20 to $15 and kept an Equal-Weight rating.

The Average Analyst Price Target for NovoCure is $26.86.

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$26.86Upside to Avg. PT+114.4%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for NovoCure Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$20→$15
Oct 30, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$23→$20
Jul 24, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$18→$20
Jul 23, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$46→$52
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$17
Jun 18, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$46
May 4, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$14→$17
May 1, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$16→$20
Apr 16, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Feb 26, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$47→$49
Feb 12, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$39→$47
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Jan 13, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$42→$39
Oct 30, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$38→$42
Oct 27, 2025	JP Morgan	Jessica Fye	PT Cut	Neutral	$25→$23
Jul 25, 2025	Wells Fargo	Larry Biegelsen	Downgrade	Overweight→Equal-Weight	$40→$15
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$30
Jun 27, 2025	Piper Sandler	Jason Bednar	Maintained	Overweight	$34
Apr 23, 2025	Piper Sandler	Jason Bednar	PT Cut	Overweight	$42→$34
Apr 16, 2025	Wedbush	David Nierengarten	PT Cut	Neutral	$29→$27